Sanofi has been hit hard by pricing pressure in diabetes, and now the drugmaker’s U.S. sales force is set for another round of job cuts.
A spokeswoman said the company is “re-aligning” its sales employees’ “commercial approach to adapt with changing market dynamics.” The company will start the layoffs in June. Sanofi doesn’t “know at this time how many employees will be impacted,” she added. All layoffs will be in the U.S.
Sanofi has been among a number of drugmakers hit by pricing pressure in diabetes in recent years. The layoffs come after the company reported a decline in 2018 sales versus 2017. For years, its diabetes outfit has been a drag, and the unit again lost ground last year. Diabetes sales slipped 13.8% to €4.5 billion in 2018. Back in 2014 and 2015, Sanofi’s diabetes group generated more than €7 billion in sales.
Amid that pressure, the French pharma has implemented a few rounds of layoffs. Last January, the company said it would cut 400 U.S. sales jobs to “adapt to the ever-changing market.” Back in 2016, Sanofi unveiled a plan to cut 20% of its U.S. diabetes sales force, or hundreds of jobs. In February 2016, the company said it would eliminate 500 positions in France. Late last year, the company planned 670 layoffs in France.
Sanofi will offer employees affected by the layoffs severance pay, health benefits and outplacement services. They can also apply for other positions in the company, Sanofi’s spokeswoman said.
Growing rebates to middlemen have been a big part of the problem for diabetes drugmakers. In February, Sanofi disclosed that it raised prices on 35 medicines last year, but that its average net prices in the U.S. fell 8%. In all, the company paid out 55% of gross sales in the form of rebates, including $4.5 billion in mandated rebates to government payers and $7.3 billion in “discretionary rebates.”
Sanofi isn’t alone, of course. Insulin rival Eli Lilly recently said the sticker price for its Humalog grew 52% over five years, but that its net price slipped 8%. Eli Lilly in 2017 announced a restructuring aimed at chopping 3,500 jobs. Novo Nordisk has suffered from pricing pressure as well; that company also responded in part by cutting costs.
On the flip side at Sanofi, the company’s Genzyme unit has been on a tear, growing sales more than 30% last year to €7.23 billion. Vaccines have also been a reliable performer in recent years.
By Eric Sagonowsky
Source: Fierce Pharma
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).